Beyond Tirzepatide: The Next-Generation Obesity Agonists Targeting Liver, Muscle, and Metabolism

The Post-GLP-1 Obesity Market Takes Shape

The weight-loss peptide market has been dominated by two drugs: semaglutide (Wegovy) and tirzepatide (Zepbound). Retatrutide, the GLP-1/GIP/glucagon triple agonist, has captured most of the "next-generation" headlines. But retatrutide isn't arriving alone. A crowded field of dual and triple agonists is advancing through Phase 2 and Phase 3 trials, each carving out differentiation not just on weight loss, but on metabolic endpoints that matter clinically: liver fat reduction, muscle preservation, and dosing schedules that improve adherence.

The takeaway from the latest pipeline data: the obesity market is about to fragment from a two-drug duopoly into a differentiated therapeutic category where liver health, body composition, and patient convenience drive prescribing decisions as much as total weight loss.

Cagrilintide and CagriSema: Targeting Satiety Through Amylin

Novo Nordisk's cagrilintide is a long-acting amylin analog—a fundamentally different mechanism from GLP-1 receptor agonism. Amylin, co-secreted with insulin from pancreatic beta cells, slows gastric emptying and signals satiety through distinct pathways in the brainstem. Novo is pairing cagrilintide with semaglutide in a fixed-ratio combination called CagriSema, which has demonstrated greater weight loss than semaglutide monotherapy in Phase 3 trials.

The differentiation here isn't just additive pounds lost—it's the dual-pathway satiety signal. Patients who plateau or experience diminishing returns on GLP-1 monotherapy may respond to the amylin component. CagriSema's clinical development is explicitly positioned around "greater weight loss" and potentially improved glycemic control through complementary mechanisms. Each peptide has its own profile on The Peptide Alliance (cagrilintide), tracking trial milestones and dosing protocols as data emerges.

Survodutide: The Liver-Focused Dual Agonist

Boehringer Ingelheim's survodutide is a GLP-1/glucagon dual agonist, but its most notable clinical endpoint to date isn't weight loss—it's liver fat reduction. Survodutide is advancing in trials for MASH (metabolic dysfunction-associated steatohepatitis, formerly known as NASH), a progressive liver disease affecting millions of patients with obesity and type 2 diabetes.

Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure, mechanisms that GLP-1 agonism alone doesn't fully activate. In mid-stage trials, survodutide has shown significant reductions in liver fat content alongside weight loss, positioning it as a potential dual-indication therapy: obesity and fatty liver disease. This matters clinically because MASH has no approved pharmacologic treatment and is projected to become the leading cause of liver transplants in the next decade. Survodutide's profile is live at survodutide, with trial updates and mechanism breakdowns.

Mazdutide: The Fast Mover in China

Less visible in Western headlines but advancing rapidly is mazdutide, another GLP-1/glucagon dual agonist developed by Eli Lilly and now licensed to Innovent Biologics for the Chinese market. Mazdutide is moving through Phase 3 trials in China with an aggressive development timeline, targeting both obesity and type 2 diabetes.

China represents the world's largest diabetes market by patient count, and mazdutide's dual-agonist profile positions it to compete directly with tirzepatide (also Lilly's) in a market where dosing convenience and metabolic efficacy—not just weight loss—drive adoption. Mazdutide's entry underscores the global fragmentation of the obesity pipeline: drugs are no longer developed for a monolithic "Western obesity market" but tailored to regional regulatory pathways, pricing structures, and clinical priorities. The peptide's mechanism and trial status are documented at mazdutide.

Differentiation Beyond the Scale

What unites cagrilintide, survodutide, and mazdutide—and separates them from the current GLP-1 standard of care—is that their clinical differentiation isn't primarily about total weight loss percentage. It's about:

• Liver health: Survodutide's focus on hepatic fat reduction targets a comorbidity that affects over a third of adults with obesity.
• Muscle preservation: Glucagon agonism may mitigate lean mass loss, a concern with rapid weight reduction on GLP-1 monotherapy.
• Dosing convenience: Long-acting formulations and fixed-ratio combinations reduce injection frequency and simplify adherence.

These aren't incremental improvements—they're the clinical endpoints that will determine formulary placement, insurance coverage, and real-world prescribing patterns once the market moves beyond "which drug causes the most weight loss."

For clinicians, compounding pharmacies, and patients tracking the pipeline, the full landscape of next-generation agonists—including retatrutide, cagrilintide, survodutide, mazdutide, and others—is documented in The State of Peptides 2026, the industry's flagship report on market dynamics, regulatory shifts, and clinical trial timelines.

This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.